Shangqian Wang
Papers
2
Total Citations
36
H-Index
2
About
Shangqian Wang is a prominent urologic surgeon and researcher whose work centers on advancing minimally invasive treatments for urologic cancers, particularly kidney and prostate malignancies. His most cited study, a 2014 systematic review and meta-analysis comparing radiofrequency ablation to partial nephrectomy for clinical stage 1 renal masses (22 citations), provided critical evidence that helped shape modern treatment paradigms for small renal tumors, demonstrating comparable oncologic outcomes with reduced morbidity for select patients. Wang further contributed to the field of prostate cancer surgery through a 2019 single-institution study (14 citations) comparing robot-assisted versus laparoscopic radical prostatectomy, offering valuable perioperative and pathological insights that guide surgical decision-making. His research, conducted at the First Affiliated Hospital, reflects a commitment to refining surgical techniques and improving patient outcomes. With a citation impact that underscores the clinical relevance of his work, Wang has established himself as a key voice in the evolution of urologic oncology, bridging the gap between traditional surgery and emerging technologies to enhance recovery and survival for cancer patients.
Research Focus
Key Achievements
Top Papers
- 1
- 2